S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Brian Weiss,Gregory A. Yanik,Arlene Naranjo,Fan F Zhang,Wendy Fitzgerald,Barry L. Shulkin,Marguerite T. Parisi,Heidi V. Russell,Stephan A. Grupp,Luke Pater,Peter Mattei,Yael P. Mosse,Hollie Lai,Jason A. Jarzembowski,Hiroyuki Shimada,Judith G. Villablanca,Roger Giller,Rochelle Bagatell,Julie R. Park,Katherine K. Matthay +19 more
TL;DR: In this paper, the authors conducted a pilot study to assess tolerability and feasibility of induction chemotherapy followed by 131 I-MIBG therapy and myeloablative busulfan/melphalan (Bu/Mel) in patients with relapsed neuroblastoma.
Journal ArticleDOI
Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation
Rakesh K. Goyal,Rakesh K. Goyal,Kelong Han,Donna A. Wall,Michael A. Pulsipher,Nancy Bunin,Stephan A. Grupp,Sripal Reddy Mada,Raman Venkataramanan +8 more
TL;DR: This study provides a rationale and support for dose adjustments of sirolimus based on steady-state blood concentrations aimed at achieving a target concentration to minimize toxicity and maximize therapeutic benefits in pediatric BMT recipients.
Journal ArticleDOI
Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies
Marco Ruella,David M. Barrett,Saad S. Kenderian,Saad S. Kenderian,Olga Shestova,Ted J. Hofmann,John Scholler,Simon F. Lacey,J. Joseph Melenhorst,Farzana Nazimuddin,Michael Kalos,Michael Kalos,David L. Porter,Carl H. June,Stephan A. Grupp,Saar Gill +15 more
TL;DR: The role of CART targeting CD123 (CART123) against r/r B-ALL, focusing on treating patients with CD19-negative relapses after prior anti-CD19 directed therapy, is investigated.
Journal Article
Cytoplasmic μ Heavy Chain Confers Sensitivity to Dexamethasone-induced Apoptosis in Early B-lineage Acute Lymphoblastic Leukemia
Jenny M. Kim,Junjie Fang,Susan R. Rheingold,Richard Aplenc,Robert Wasserman,Stephan A. Grupp +5 more
TL;DR: A role for the pre-BCR complex is suggested in the response of ALL cells to treatment and insight is provided into the mechanism of steroid response in the treatment of pre-B ALL.
Journal ArticleDOI
Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol
Paul G. Richardson,Angela R. Smith,Stephan A. Grupp,Nancy A. Kernan,Sally Arai,Paul R. Haut,Brandon M. Triplett,Alfred P. Gillio,Heather J. Symons,Roberta H. Adams,Biljana Horn,Kenneth G. Lucas,Paul L. Martin,Shin Mineishi,Edward D. Ball,Michael Boyer,John Fort,Ivan I. Kirov,Leslie Lehmann,Catherine Madigan,Michelle E. Maglio,Joseph M. Massaro,Ralph B. D'Agostino,Alison L. Hannah,Elena Tudone,Robin Hume,Massimo Iacobelli,Robert J. Soiffer +27 more
TL;DR: In 269 pts with mainly sVOD/MOF, DF therapy achieved significantly improved outcome compared to an untreated historical control, and CR and survival were improved in pts who were treated within 2d of VOD diagnosis (vs. later).